Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics
- PMID: 37353457
- PMCID: PMC10526725
- DOI: 10.1016/j.hlc.2023.05.016
Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics
Abstract
Ventricular arrhythmias (VAs) represent a major cause of sudden cardiac death and afflict patients with heart failure from both ischaemic and non-ischaemic origins, and inherited cardiomyopathies. Current VA management, including anti-arrhythmic medications, autonomic modulation, implantable cardioverter-defibrillator implantation, and catheter ablation, remains suboptimal. Catheter ablation may even cause significant cardiomyocyte loss. Cell-based therapies and exosome treatment have been proposed as promising strategies to lessen cardiomyocyte death, modulate immune reaction, and reduce myocardial scarring, and, therefore, are potentially beneficial in treating VAs. In this review, we summarise the current cornerstones of VA management. We also discuss recent advances and ongoing evidence regarding cell-based and exosome therapy, with special attention to VA treatment.
Keywords: Cardiosphere-derived cells; Catheter ablation; Exosomes; Extracellular Vesicles; Stem cells; Ventricular arrhythmias.
Copyright © 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.
Figures
References
-
- Gräni C, Benz DC, Gupta S, Windecker S, Kwong RY. Sudden cardiac death in ischemic heart disease: from imaging arrhythmogenic substrate to guiding therapies. JACC: Cardiovasc Imaging. 2020;13:2223–38. - PubMed
-
- Kirubakaran S, Bisceglia C, Silberbauer J, Oloriz T, Santagostino G, Yamase M, et al. Characterization of the arrhythmogenic substrate in patients with arrhythmogenic right ventricular cardiomyopathy undergoing ventricular tachycardia ablation. EP Europace. 2017;19:1049–62. - PubMed
-
- Pappone C, Ciconte G, Manguso F, Vicedomini G, Mecarocci V, Conti M, et al. Assessing the malignant ventricular arrhythmic substrate in patients with Brugada syndrome. J Am Coll Cardiol. 2018;71:1631–46. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
